AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
Continuity Biosciences, LLC, a new bioscience company dedicated to developing and commercializing cutting-edge technologies ...
Possibly the biggest news this week comes from the schizophrenia space, where AbbVie’s emraclidine failed two mid-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback